Autologous bone marrow derived mesenchymal stem cells are safe for the treatment of Achilles tendinopathy

Andrew J. Goldberg,Lorenzo Masci,Paul O'Donnell,Ruth Green,Deirdre Brooking,Paul Bassett,Mark W. Lowdell,Roger K. W. Smith

DOI: https://doi.org/10.1038/s41598-024-61399-3

IF: 4.6

2024-05-20

Scientific Reports

Abstract:Achilles tendinopathy is a disabling condition that affects more than 50% of runners. Pre-clinical studies in a large animal model of naturally-occurring tendinopathy similar to human Achilles tendinopathy has shown benefits of autologous bone marrow-derived mesenchymal stem cell (MSC) implantation. However, MSCs are advanced therapies medicinal products (ATMPs), with strict regulatory requirements. Guided by the regulator we carried out a first in man study to assess the safety and efficacy of autologous MSC injection in human patients with non-insertional Achilles tendinopathy. Ten patients, mean age 47 with mid-portion Achilles tendon pain and swelling for more than 6 months, underwent autologous cultured cell injections (median 12.2 × 10 6 , range 5–19 × 10 6 cells) into their Achilles tendon. At 24 weeks follow-up, no serious adverse reactions or important medical events were observed. MOXFQ, EQ-5D-5L, and VISA-A scores improved clinically at 12 and 24 weeks. VAS pain improved increasingly at 6, 12 and 24 weeks. MOXFQ Pain and VISA-A Scores improved > 12 points from baseline to 24 weeks in 8 patients. Maximum anteroposterior tendon thickness as measured by greyscale US decreased by mean 0.8 mm at 24 weeks. This phase IIa study demonstrated the safety of autologous MSC injection for non-insertional Achilles tendinopathy and provides proof-of-concept of the technique in patients, all of whom had previously failed conservative treatments for chronic disease and leads the way for a larger randomised controlled trial.

multidisciplinary sciences

What problem does this paper attempt to address?

The aim of this paper is to address the issue of evaluating the safety and efficacy of autologous bone marrow-derived mesenchymal stem cells (BMMSCs) injection for the treatment of non-insertional Achilles tendinopathy (AT).

Specifically:
- **Background Issue**: Achilles tendinopathy is a common degenerative condition that leads to chronic pain and functional impairment. Current non-surgical treatment methods have varying effectiveness and lack robust data support.
- **Research Objective**: To conduct the first human trial under regulatory guidance to assess the safety and preliminary efficacy of autologous cultured BMMSCs injection for the treatment of non-insertional Achilles tendinopathy.
- **Study Design**: This is a single-arm, open-label Phase IIa proof-of-concept study aimed at determining the safety of BMMSCs injection and providing preliminary efficacy evidence to lay the groundwork for subsequent larger-scale randomized controlled trials.
- **Main Results**: The study results showed no serious adverse reactions or significant medical events in 10 patients, and the clinical symptoms of the patients improved significantly. These patients had previously tried various conservative treatment methods without success.

Overall, the main purpose of this study is to verify the safety and potential efficacy of autologous BMMSCs injection for the treatment of Achilles tendinopathy, providing a basis for future large-scale clinical trials.